MindWalk Holdings (HYFT) Amortization - Intangibles (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Amortization - Intangibles of $374.7 for Q1 2026, down 99.9% year-over-year from $366302.0 in Q1 2025, and up 2.52% quarter-over-quarter from $365.49 in Q4 2025.
MindWalk Holdings (HYFT) Amortization - Intangibles (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Amortization - Intangibles for 6 consecutive years, with $374.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles fell 99.9% year-over-year to $374.7; the TTM figure through Apr 2026 stood at $740.18 (down 100.0% YoY), while the FY2025 annual figure was $1.1 million, down 37.35% from the prior year.
- Amortization - Intangibles improved to $374.7 in Q1 2026 per HYFT's latest filing, from $365.49 in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $634.6 million in Q3 2023 and bottomed at $365.49 in Q4 2025.
- Historically, Amortization - Intangibles has averaged $117.7 million across 5 years, with a median of $524462.5 in 2024.
- Annual changes were most pronounced in 2023 — Amortization - Intangibles surged 62587.26% — and 2024, when it plunged 99.93%.
- MindWalk Holdings' Amortization - Intangibles stood at $836466.8 in 2022, then soared by 62587.26% to $524.4 million in 2023, then slumped by 99.93% to $371270.4 in 2024, then tumbled by 99.9% to $365.49 in 2025, then rose by 2.52% to $374.7 in 2026.
- Business Quant data shows HYFT's Amortization - Intangibles at $374.7 in Q1 2026, $365.49 in Q4 2025, and $492.61 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 374.70 |
| Oct 31, 2025 | 365.49 |
| Apr 30, 2025 | 492.61 |
| Jan 31, 2025 | 366,301.96 |
| Oct 31, 2024 | 371,270.37 |
| Jul 31, 2024 | 366.62 Mn |
| Apr 30, 2024 | 73,014.51 |
| Jan 31, 2024 | 524,462.53 |
| Oct 31, 2023 | 524.36 Mn |
| Jul 31, 2023 | 634.58 Mn |
| Apr 30, 2023 | 973,327.77 |
| Jan 31, 2023 | 765,860.44 |
| Oct 31, 2022 | 836,466.82 |
| Jan 31, 2021 | 727,699.13 |